18547871. DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC simplified abstract (The Regents of the University of California)
Contents
DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC
Organization Name
The Regents of the University of California
Inventor(s)
Steven Altschuler of San Francisco CA (US)
Lani Wu of San Francisco CA (US)
Xiaoxiao Sun of San Francisco CA (US)
Matthew Jacobson of San Francisco CA (US)
DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC - A simplified explanation of the abstract
This abstract first appeared for US patent application 18547871 titled 'DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC
- Simplified Explanation:**
The patent application discusses methods and compositions for treating cancers that are resistant to certain drug treatments, particularly in subjects with elevated STAT1 activity levels.
- Key Features and Innovation:**
- Methods for treating drug-resistant cancers - Composition for targeting elevated STAT1 activity levels - Focus on addressing recalcitrant cancers
- Potential Applications:**
- Cancer treatment in patients with drug-resistant tumors - Precision medicine for individuals with elevated STAT1 activity levels - Research in personalized cancer therapies
- Problems Solved:**
- Overcoming drug resistance in cancer treatment - Targeting specific molecular pathways in cancer cells - Improving outcomes for patients with recalcitrant cancers
- Benefits:**
- Enhanced efficacy in treating resistant cancers - Personalized treatment options based on molecular profiles - Potential for improved survival rates in patients
- Commercial Applications:**
- Precision oncology services for personalized cancer treatment - Development of targeted therapies for drug-resistant tumors - Potential partnerships with pharmaceutical companies for drug development
- Questions about Cancer Treatment:**
1. How does elevated STAT1 activity contribute to drug resistance in cancers? 2. What are the implications of targeting specific molecular pathways in cancer therapy?
Original Abstract Submitted
Provided herein are, inter alia, methods and composition for the treatment of cancers that are recalcitrant to treatment and/or become resistant to certain drug treatments. The methods provided may, inter alia, be used to treat cancer in subjects having elevated STAT1 activity levels.